Menu

Latest Pharma Insights



Wearable Data Glut Meets Proof And Payment Gaps, Milken Panelists Say
Patients are awash in wearable data, but panelists at the Milken Institute Future of Health Summit said turning it into better outcomes depends on payment models that reward AI-enabled care, validated metrics and clinicians willing to collaborate.
Medtech Insight - November 18, 2026
China Basic Medical Insurance Covers CAR-T For First Time
China has included a CAR-T therapy for the first time in its revised national drug reimbursement list, along with a siRNA drug, while a gene therapy was added to commercial insurance coverage.
Pink Sheet - November 18, 2026
White House Pulls Overton’s US FDA Commissioner Nomination Despite Cassidy Seeing Path
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy said Heidi Overton’s nomination for FDA commissioner died because of the White House, not a lack of votes.
HBW Insight - November 18, 2026
Proposed US Rule May Boost Supplement Industry Chances In ‘Race To Market’ For New Ingredients
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
Harry’s Marketer Questions NARB Appeals Process Amid FTC Referral
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026

China Basic Medical Insurance Covers CAR-T For First Time
China has included a CAR-T therapy for the first time in its revised national drug reimbursement list, along with a siRNA drug, while a gene therapy was added to commercial insurance coverage.
Pink Sheet - November 18, 2026

Wearable Data Glut Meets Proof And Payment Gaps, Milken Panelists Say
Patients are awash in wearable data, but panelists at the Milken Institute Future of Health Summit said turning it into better outcomes depends on payment models that reward AI-enabled care, validated metrics and clinicians willing to collaborate.
Medtech Insight - November 18, 2026

White House Pulls Overton’s US FDA Commissioner Nomination Despite Cassidy Seeing Path
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy said Heidi Overton’s nomination for FDA commissioner died because of the White House, not a lack of votes.
HBW Insight - November 18, 2026
Proposed US Rule May Boost Supplement Industry Chances In ‘Race To Market’ For New Ingredients
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
Harry’s Marketer Questions NARB Appeals Process Amid FTC Referral
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026

Fresenius Kabi Enters Canada’s Crowded Denosumab Biosimilar Market With Oncology Pre-Filled Syringe
Fresenius Kabi has launched its denosumab biosimilars Bomyntra and Conexxence in Canada, saying it is the only biosimilar maker with a pre-filled syringe for oncology.
Generics Bulletin - November 17, 2026
Rosemont Bolsters US Ambitions By Paying $56m For Aytu BioPharma
Rosemont Pharmaceuticals has furthered its international expansion strategy by striking a deal worth $56m to acquire US specialty player Aytu BioPharma.
Generics Bulletin - November 17, 2026
Towa’s Core Business Growth Offset By Sunsho Pharmaceuticals’ Struggles
As Towa announces interim results for the six-month period ending Sept. 30, 2026, concerns continue to mount over the Japanese firm’s struggling subsidiary, Sunsho Pharmaceuticals.
Generics Bulletin - November 17, 2026

Strategic Intent: Praxis CEO On “Unlearning,” AI And Launching Two Neuroscience Drugs At Once
In this episode of Strategic Intent, Praxis CEO Marcio Souza explains how unlearning, AI fluency and patient-centered trial design shaped its turnaround as it readies two very different neuroscience drug launches.
In Vivo - November 17, 2026